---
title: "Infinium Pharmachem Ltd (INFINIUM) — Share Price, Financials & Analysis"
symbol: "INFINIUM"
company: "Infinium Pharmachem Ltd"
canonical: "https://tapetide.com/stocks/INFINIUM"
isin: "INE0MRE01011"
nse_symbol: "INFINIUM"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 405.16
generated_at: "2026-09-13T19:25:30.772Z"
---

# Infinium Pharmachem Ltd (INFINIUM)

Canonical page: https://tapetide.com/stocks/INFINIUM

## Company

- **NSE Symbol:** INFINIUM
- **ISIN:** INE0MRE01011
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-04-17
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** infiniumpharmachem.com

## About

Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]

## Latest Price

- **Price:** ₹266.2
- **Change:** -7.8 (-2.85%)
- **Open:** ₹260
- **Day High:** ₹270
- **Day Low:** ₹257
- **Previous Close:** ₹274
- **Volume:** 6500
- **As Of:** 2026-09-11T09:48:46+00:00

## Key Fundamentals

Observed at 2026-09-11T04:46:47.874419Z.

- **Market Cap:** ₹405.16 Cr
- **Classification:** SME
- **P/E (reported):** 30.1
- **Book Value:** ₹77.68
- **Price to Book:** 3.53
- **Dividend Yield:** 0%
- **ROE:** 6.28%
- **ROCE:** 11.31%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹189.63 Cr
- **Net Income:** ₹14.11 Cr
- **EBITDA:** ₹21.56 Cr
- **52-Week High:** ₹285.5
- **52-Week Low:** ₹189.4
- **RSI (14):** 62.9

## Tapetide Score

- **Score:** 69 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 99.3 (of 4473 scored stocks)
- **Confidence:** 88%
- **Data coverage:** 76%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 77.51 | 9% |
| growth | 68.43 | 9% |
| momentum | 86.03 | 12% |
| ownership | 68.66 | 24% |
| quality | 92.35 | 22% |
| valuation | 42.38 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Promoter holding has increased by 5.00% over last quarter.

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 14.0% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | -123.31% | -439% | -499.45% |
| ebitda margin growth | -4.26% | -23.17% | 2.55% |
| net income growth | 80.9% | 9% | 35% |
| revenue growth | 20.17% | 18% | 22% |
| roce | -55.79% | -76.16% | 31.94% |
| roe | -67.12% | 22.22% | -83.4% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2022 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 79 | 61 | 74 | 83 | 73 | 84 | 106 |
| Expenses | 71 | 51 | 66 | 75 | 65 | 74 | 94 |
| Operating Profit | 9 | 10 | 8 | 8 | 8 | 10 | 11 |
| OPM % | 11 | 17 | 11 | 10 | 11 | 12 | 11 |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Depreciation | 0 | 1 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 8 | 8 | 7 | 6 | 5 | 8 | 10 |
| Tax % | 22 | 24 | 24 | 25 | 41 | 22 | 19 |
| Net Profit | 6 | 6 | 5 | 5 | 3 | 7 | 8 |
| EPS in Rs | 5.4 | 4.46 | 3.66 | 3.17 | 2.4 | 3.59 | 4.2 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 39 | 71 | 99 | 114 | 136 | 156 | 190 |
| Expenses | 36 | 66 | 89 | 98 | 117 | 136 | 168 |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 19 | 22 |
| OPM % | 6 | 7 | 10 | 14 | 14 | 12 | 11 |
| Other Income | 1 | 1 | 1 | 1 | 2 | -1 | 2 |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| Profit before tax | 1 | 4 | 9 | 13 | 15 | 12 | 18 |
| Tax % | 30 | 28 | 23 | 24 | 24 | 32 | 20 |
| Net Profit | 1 | 3 | 7 | 10 | 12 | 8 | 14 |
| EPS in Rs | 4.65 | 13.6 | 30.55 | 9.3 | 8.12 | 5.23 | 7.8 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 105 |
| Borrowings | 9 | 11 | 23 | 29 | 11 | 52 | 0 |
| Other Liabilities | 9 | 17 | 23 | 19 | 15 | 37 | 54 |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 175 |
| Fixed Assets | 4 | 5 | 4 | 19 | 20 | 24 | 23 |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| Other Assets | 18 | 26 | 46 | 52 | 66 | 144 | 114 |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 175 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 3 | 7 | 12 | 9 | -13 | -29 | 34 |
| Cash from Investing Activity | -1 | -5 | -7 | -5 | -4 | -27 | -7 |
| Cash from Financing Activity | -1 | -1 | -2 | -3 | 23 | 79 | -32 |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 | -5 |
| Free Cash Flow | 2 | 2 | 7 | 1 | -17 | -38 | 24 |
| CFO/OP | 137 | 168 | 137 | 73 | -51 | -131 | 174 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 | 61 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 | 10 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working Capital Days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
| ROCE % | — | 32 | 38 | 36 | 28 | 15 | 13 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 100% | 73.05% | 73.05% | 73.05% | 65.24% | 59.91% | 64.91% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0.22% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 23.96% | 23.85% | 23.97% | 32% | 37.21% | 31.96% |
| Others | 0% | 2.99% | 3.1% | 2.98% | 2.76% | 2.88% | 2.91% |
| No. of Shareholders | 17 | 646 | 771 | 947 | 958 | 1052 | 1061 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 4 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 267.42 | Sell |
| EMA (10) | 267.06 | Sell |
| SMA (20) | 254.99 | Buy |
| EMA (20) | 256.64 | Buy |
| SMA (50) | 229.2 | Buy |
| EMA (50) | 237.65 | Buy |
| SMA (100) | 219.39 | Buy |
| EMA (100) | 227.39 | Buy |
| SMA (200) | 219.31 | Buy |
| EMA (200) | 227.85 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 58.16 | Neutral |
| MACD (12,26,9) | 13.61 | Buy |
| Stochastic (14,3,3) | 81.72 | Sell |
| ADX (14) | 27.71 | Buy |
| Williams %R (14) | -32.91 | Neutral |
| ATR (14) | 13.2 | High Volatility |
| ROC (12) | -0.93 | Sell |
| Stoch RSI (14) | 9.55 | Buy |
| UO (7,14,28) | 59.68 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8 January 2026 - 03 Jan 2026 certificate for quarter ended 31 Dec 2025: Reg74(5) not applicable; all shares demat, no remat requests. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 8 January 2026 - 03 Jan 2026 certificate for quarter ended 31 Dec 2025: Reg74(5) not applicable; all shares demat, no remat requests.](https://nsearchives.nseindia.com/corporate/INFINIUM1_08012026164645_final_pdf.pdf) |
| 8 April 2026 - Regulation 74(5) certificate for quarter ended March 31, 2026 confirms no rematerialisation requests. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 8 April 2026 - Regulation 74(5) certificate for quarter ended March 31, 2026 confirms no rematerialisation requests.](https://nsearchives.nseindia.com/corporate/INFINIUM1_08042026114123_Final_pdf_.pdf) |
| 29 May - Infinium Pharmachem Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. | [Outcome of Board Meeting 29 May - Infinium Pharmachem Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/INFINIUM1_29052026134717_outcome_final.pdf) |
| 29 April 2026 - Submitted SDD compliance certificate for year ended March 31, 2026. | [Structural Digital Database 29 April 2026 - Submitted SDD compliance certificate for year ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/INFINIUM1_29042026123005_Final_pdf.pdf) |
| 27 March 2026 - Trading window closed from 1 April 2026 until 48 hours after FY2025-26 results declaration. | [Trading Window 27 March 2026 - Trading window closed from 1 April 2026 until 48 hours after FY2025-26 results declaration.](https://nsearchives.nseindia.com/corporate/INFINIUM1_27032026152559_Intimation.pdf) |
| 27 Aug - Infinium Pharmachem schedules Group Institutional Investor meeting and site visit on 3 September 2026 in Anand. | [Analysts/Institutional Investor Meet/Con. Call Updates 27 Aug - Infinium Pharmachem schedules Group Institutional Investor meeting and site visit on 3 September 2026 in Anand.](https://nsearchives.nseindia.com/corporate/INFINIUM1_27082026160645_Intimation_Investors_Meet.pdf) |
| 26 Aug - Newspaper advertisements published for Infinium Pharmachem's postal ballot notice on August 26, 2026. | [Copy of Newspaper Publication 26 Aug - Newspaper advertisements published for Infinium Pharmachem's postal ballot notice on August 26, 2026.](https://nsearchives.nseindia.com/corporate/INFINIUM1_26082026151543_NSE_newspaper.pdf) |
| 26 Aug - AGM scheduled for 17 September 2026; record date fixed as 10 September 2026 for remote e-voting. | [Record Date 26 Aug - AGM scheduled for 17 September 2026; record date fixed as 10 September 2026 for remote e-voting.](https://nsearchives.nseindia.com/corporate/INFINIUM1_26082026151927_IPL_INTIMATION.pdf) |
| 25 Aug - Postal ballot seeks migration from NSE Emerge to NSE Main Board; e-voting runs 28 Aug-26 Sep 2026. | [Shareholders meeting 25 Aug - Postal ballot seeks migration from NSE Emerge to NSE Main Board; e-voting runs 28 Aug-26 Sep 2026.](https://nsearchives.nseindia.com/corporate/INFINIUM1_25082026171601_Postal_Ballot_Notice.pdf) |
| 25 Aug - Newspaper ad issued for 22nd AGM notice, record date, and e-voting information. | [Copy of Newspaper Publication 25 Aug - Newspaper ad issued for 22nd AGM notice, record date, and e-voting information.](https://nsearchives.nseindia.com/corporate/INFINIUM1_25082026171019_NSE_newspaper.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30519_INFINIUM_2025_2026_A_2216015_22082026172907.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27828_INFINIUM_2024_2025_A_11804639_28082025182205.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_26001_INFINIUM_2023_2024_0609202417430.pdf) |
| from nse | [Financial Year 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_22612_INFINIUM_2022_2023_02082023165041_08022023170004.zip) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Mar 2024 | [Concall - Mar 2024](https://nsearchives.nseindia.com/corporate/INFINIUM_13032024144313_Trans.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://nsearchives.nseindia.com/corporate/INFINIUM_15062024114919_Transcript.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:25:30.772Z.